Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
LUME-Meso trial: what clinicians have said so far
Nintedanib (BIBF 1120) in Mesothelioma
- NCT01907100 ↗
- Terminated
- Boehringer Ingelheim
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on LUME-Meso (nintedanib in unresectable malignant pleural mesothelioma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LUME-Meso so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X |
The trial
ClinicalTrials.gov- Official title
- LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma
- Phase
- Phase 2/Phase 3
- Status
- Terminated
- Conditions
- Mesothelioma
- Interventions
- Nintedanib; Pemetrexed; Cisplatin; Cisplatin; Pemetrexed; Placebo
- Arms
- Placebo + pemetrexed/cisplatin · Placebo comparator
- Nintedanib 200mg + pemetrexed/cisplatin · Experimental
- Enrollment
- 545
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 19, 2013
- Primary completion
- Mar 16, 2018
- Results posted
- Yes
- Registry record
- NCT01907100 · updated Mar 18, 2019
Publications
linked from the registry- Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sorensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15. PubMed 31103412